Article Dans Une Revue Nature Communications Année : 2024

Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Résumé

No abstract available

Dates et versions

hal-04751234 , version 1 (24-10-2024)

Identifiants

Citer

Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.4753. ⟨10.1038/s41467-024-48915-9⟩. ⟨hal-04751234⟩
87 Consultations
0 Téléchargements

Altmetric

Partager

  • More